| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 35356-0210-30 | 35356-0210 | Dutasteride | Avodart | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Mar 26, 2012 | Dec 31, 2016 | No Longer Used |
| 31722-0131-90 | 31722-0131 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 7, 2016 | In Use | |
| 50090-7305-00 | 50090-7305 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Oct 14, 2024 | In Use | |
| 60505-3877-03 | 60505-3877 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 25, 2015 | Jan 31, 2021 | No Longer Used |
| 72578-0019-06 | 72578-0019 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Apr 15, 2019 | In Use | |
| 73116-0225-28 | 73116-0225 | Duvelisib | COPIKTRA | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 73116-0215-28 | 73116-0215 | Duvelisib | COPIKTRA | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 71779-0125-02 | 71779-0125 | duvelisib | Copiktra | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 73116-0115-01 | 73116-0115 | duvelisib | COPIKTRA | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 73116-0225-56 | 73116-0225 | Duvelisib | COPIKTRA | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 28, 2018 | In Use | |
| 73116-0115-02 | 73116-0115 | duvelisib | COPIKTRA | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 71779-0115-01 | 71779-0115 | duvelisib | Copiktra | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 73116-0125-02 | 73116-0125 | duvelisib | COPIKTRA | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 73116-0125-01 | 73116-0125 | duvelisib | COPIKTRA | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 73116-0215-56 | 73116-0215 | Duvelisib | COPIKTRA | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 71779-0125-01 | 71779-0125 | duvelisib | Copiktra | 25.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 71779-0115-02 | 71779-0115 | duvelisib | Copiktra | 15.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Sep 25, 2018 | In Use | |
| 72893-0016-02 | 72893-0016 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
| 73491-0627-01 | 73491-0627 | Efbemalenograstim alfa-vuxw | RYZNEUTA | 20.0 mg/mL | Immunotherapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Subcutaneous | Nov 23, 2023 | In Use | |
| 82497-0132-01 | 82497-0132 | Eflapegrastim-xnst | Rolvedon | 13.2 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Dec 11, 2025 | In Use | |
| 76961-0101-01 | 76961-0101 | Eflapegrastim-xnst | Rolvedon | 13.2 mg/.6mL | Ancillary Therapy | Immunostimulant | Granulocyte colony stimulating factor | Subcutaneous | Oct 18, 2022 | In Use | |
| 72187-0102-03 | 72187-0102 | Elacestrant | ORSERDU | 345.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan 27, 2023 | In Use | |
| 72187-0101-03 | 72187-0101 | Elacestrant | ORSERDU | 86.0 mg/1 | Hormonal Therapy | Estrogen Receptor Antagonist | ERα | Oral | Jan 27, 2023 | In Use | |
| 00003-4522-11 | 00003-4522 | Elotuzumab | Empliciti | 400.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov 30, 2015 | In Use | |
| 00003-2291-11 | 00003-2291 | Elotuzumab | Empliciti | 300.0 mg/1 | Immunotherapy | Monoclonal Antibody | SLAMF7 | Intravenous | Nov 30, 2015 | In Use |
Found 12159 results — Export these results
Home